Coherus Oncology (CHRS) EPS (Basic) Growth (3y) (2016 - 2026)
Coherus Oncology (CHRS) EPS (Basic) Growth (3y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.95 Bn | 132.10 Bn | 2.84 Bn | 6.85% |
| 2 | Regeneron Pharmaceuticals | 86.71 Bn | 78.72 Bn | 3.93 Bn | 11.71% |
| 3 | Argenx Se | 65.71 Bn | 60.52 Bn | 1.37 Bn | 64.84% |
| 4 | Moderna | 60.45 Bn | 55.31 Bn | 52.00 Mn | 18.44% |
| 5 | BeOne Medicines | 42.24 Bn | 37.14 Bn | 1.53 Bn | 37.21% |
| 6 | Alnylam Pharmaceuticals | 31.80 Bn | 28.49 Bn | 992.69 Mn | 36.73% |
| 7 | BioNTech SE | 28.64 Bn | 10.25 Bn | 668.28 Mn | -26.87% |
| 8 | Insmed | 27.61 Bn | 26.45 Bn | 358.27 Mn | 67.51% |
| 9 | Royalty Pharma | 27.26 Bn | 26.42 Bn | - | -38.31% |
| 10 | Coherus Oncology | 210.55 Mn | 105.25 Mn | 10.07 Mn | 35.26% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 29.41% |
| Mar 31, 2026 | 77.98% |
| Dec 31, 2025 | 28.02% |
| Sep 30, 2025 | 27.43% |
| Jun 30, 2025 | 87.24% |
| Mar 31, 2025 | 60.07% |
| Dec 31, 2024 | 59.51% |
| Sep 30, 2024 | 38.49% |
| Jun 30, 2024 | 42.98% |
| Mar 31, 2024 | 38.18% |
| Dec 31, 2023 | -101.84% |
| Sep 30, 2023 | -47.65% |
| Jun 30, 2023 | -39.20% |
| Mar 31, 2023 | -58.72% |
| Dec 31, 2022 | -50.56% |
| Sep 30, 2022 | -55.61% |
| Jun 30, 2022 | -58.77% |
| Mar 31, 2022 | -62.60% |
| Dec 31, 2021 | 14.32% |
| Sep 30, 2021 | 17.46% |